Skip to content
Open access

Comparative effectiveness of CAR-T cell therapy and CD20xCD3 bispecific antibodies in relapsed/refractory follicular lymphoma: A propensity score–matched real-world analysis.

Oct 2026 · JCO Oncology Practice · 0 citations

Abstract

639 Background: CD20×CD3 bispecific antibodies and chimeric antigen receptor T-cell (CAR-T) therapy have expanded treatment options for relapsed/refractory follicular lymphoma (R/R FL). Although both therapies demonstrate substantial clinical activity, comparative real-world data remain limited. We compared survival and treatment-related outcomes between patients treated with CD20×CD3 bispecific antibodies and CAR-T therapy. Methods: We conducted a retrospective cohort study using the TriNetX Global Collaborative Network, a federated electronic health record database. Adult patients with follicular lymphoma treated with CD20×CD3 bispecific antibodies (mosunetuzumab, epcoritamab, glofitamab, or odronextamab) or CAR-T therapy were identified. After propensity score matching for 57 demographic and clinical covariates, 434 patients remained in the bispecific antibody cohort and 432 in the CAR-T cohort. Outcomes assessed included all-cause mortality, acute kidney injury (AKI), sepsis, histologic transformation to diffuse large B-cell lymphoma (DLBCL), hypogammaglobulinemia, hematologic toxicities, thromboembolic events, and cerebrovascular complications. Results: After matching, CD20×CD3 bispecific antibodies were associated with significantly lower all-cause mortality compared with CAR-T therapy (21.9% vs 29.2%; RR 0.75, OR 0.68, p=0.014). Kaplan–Meier analysis demonstrated higher survival probabilities (67.3% vs 51.6%). AKI occurred less frequently in the bispecific antibody cohort (11.1% vs 21.1%; RR 0.53, OR 0.47, p=0.001). Rates of sepsis, neutropenia, pulmonary embolism, venous thromboembolism, and cerebral infarction were similar. Histologic transformation to DLBCL was significantly lower with bispecific antibodies (8.3% vs 17.4%; RR 0.48, OR 0.43, p=0.020), with higher transformation-free survival (87.0% vs 55.8%). Hypogammaglobulinemia was less frequent among bispecific antibody recipients (25.1% vs 57.0%; RR 0.44, OR 0.25, p<0.001), with a lower hazard of development (HR 0.35, 95% CI 0.24–0.50, p<0.001). Conclusions: In this large propensity score-matched real-world analysis of R/R FL, CD20×CD3 bispecific antibodies were associated with lower mortality and reduced treatment-related toxicity compared with CAR-T therapy. Rates of infectious and thromboembolic complications were similar, while risks of AKI, hypogammaglobulinemia, and histologic transformation to DLBCL were significantly lower. These findings suggest that CD20×CD3 bispecific antibodies represent an effective and potentially safer therapeutic alternative to CAR-T therapy in selected patients with R/R FL and warrant prospective validation.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.